Menzies Institute for Medical Research, University of Tasmania, 17 Liverpool St, 7000 Hobart, Australia.
Sports Cardiology, Baker Heart and Diabetes Institute, 99 Commercial Rd, Melbourne 3000, Australia.
Eur J Prev Cardiol. 2023 Aug 21;30(11):1101-1117. doi: 10.1093/eurjpc/zwad028.
Prevention of cardiovascular disease (CVD) remains one of the largest public health challenges of our time. Identifying individuals at increased cardiovascular risk at an asymptomatic, sub-clinical stage is of paramount importance for minimizing disease progression as well as the substantial health and economic burden associated with overt CVD. Vascular ageing (VA) involves the deterioration in vascular structure and function over time and ultimately leads to damage in the heart, brain, kidney, and other organs. Vascular ageing encompasses the cumulative effect of all cardiovascular risk factors on the arterial wall over the life course and thus may help identify those at elevated cardiovascular risk, early in disease development. Although the concept of VA is gaining interest clinically, it is seldom measured in routine clinical practice due to lack of consensus on how to characterize VA as physiological vs. pathological and various practical issues. In this state-of-the-art review and as a network of scientists, clinicians, engineers, and industry partners with expertise in VA, we address six questions related to VA in an attempt to increase knowledge among the broader medical community and move the routine measurement of VA a little closer from bench towards bedside.
预防心血管疾病(CVD)仍然是我们这个时代最大的公共卫生挑战之一。在无症状、亚临床阶段识别心血管风险增加的个体对于最大限度地减少疾病进展以及与明显 CVD 相关的大量健康和经济负担至关重要。血管老化(VA)涉及血管结构和功能随时间的恶化,最终导致心脏、大脑、肾脏和其他器官的损伤。血管老化包含了所有心血管危险因素在生命过程中对动脉壁的累积影响,因此可以帮助在疾病早期识别那些处于升高的心血管风险中的人。尽管 VA 的概念在临床上越来越受到关注,但由于缺乏关于如何将 VA 特征化为生理与病理以及各种实际问题的共识,因此在常规临床实践中很少测量 VA。在这篇最新的综述中,我们作为一个由血管老化方面的专家——科学家、临床医生、工程师和行业合作伙伴组成的网络,回答了与 VA 相关的六个问题,旨在提高更广泛的医学界的知识水平,并使 VA 的常规测量从实验室更接近临床。